Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 20th Preview)
-
Inflammation / Inflammatory bowel disease pipeline momentum
Gilead advanced its immunology diversification with mid-stage data for emvistegrast in ulcerative colitis. In the SWIFT Phase 2 study presented at United European Gastroenterology Week in Barcelona, the oral a4b7 integrin blocker delivered clinical response rates of 66% with the 200 mg dose versus 37% on placebo, supporting the program’s primary endpoint. Gilead tested three emvistegrast doses (200 mg, 75 mg, 25 mg) in 238 patients with moderately to severely active ulcerative colitis. The 75 mg and 25 mg cohorts posted response rates of 51% and 43%, respectively, with the company planning a Phase 3 start next year and additional Crohn’s disease development. Analysts at BMO Capital Markets said the results “validate” Gilead’s inflammatory push, noting competitiveness versus other a4b7 agents such as Eli Lilly’s zotemtegrast. Truist highlighted that dose response is not perfectly aligned on secondary endpoints, pointing to where the Phase 3 data will need to tighten.
-
Biotech dealmaking: rare disease RNA platform expansion
Merck KGaA struck a major rare-disease acquisition, agreeing to buy Silence Therapeutics for $1.3 billion in an all-cash deal. The transaction adds divesiran, Silence’s wholly owned siRNA candidate aimed at polycythemia vera by silencing TMPRSS6 in the liver to raise hepcidin and limit iron availability for excess red blood cell production. Deal terms call for Silence shareholders to receive $20.00 per ADS, valuing the offer about 48% above Silence’s August $13.50 per ADS price. Merck KGaA said it expects closing in the first quarter of 2027 and will keep both companies operating independently until then. In parallel, Silence’s PV readouts in August have been positioned as a strategic catalyst for the acquisition, extending Merck’s rare disease reach and adding a late-stage hematology entry point to its pipeline transformation strategy.
-
Diagnostics M&A: broaden prostate cancer risk testing footprint
Labcorp moved to deepen its diagnostics presence with an agreement to absorb BioReference assets in a deal valued at $722 million. The transaction targets BioReference’s laboratory testing operations spanning clinical and women’s health testing, urology and corrections services, plus additional patient service centers expected to integrate into Labcorp’s network. A key component is the FDA-approved 4Kscore Test, designed to predict the likelihood of detecting aggressive prostate cancer before biopsy. Labcorp said expanding access to 4Kscore and other specialty testing capabilities will broaden patient and provider reach, while maintaining existing services until regulatory approvals and customary closing conditions are met. The deal structure includes an earnout of up to $150 million tied to revenue from the 4Kscore Test. Labcorp projected approximately $250 million in revenue during the first year post-close based on forecasts.
-
Oncology pipeline: antibody-like immune engineering enters early clinical testing
A new Phase 1 signal emerged for an engineered NK/T-cell engagement strategy in advanced non-small cell lung cancer. In nine patients, Rapport’s investigational NK510 program—described as TIGIT-disrupted NK510—combined with PD-1 blockade showed preliminary safety without observed dose-limiting toxicities. The study reported highly uncertain early efficacy estimates, with the main near-term readout focused on tolerability in a heavily pretreated population typical of early-phase oncology trials. Trial activity suggests the platform may support further dose-escalation and expansion cohorts. For drug developers, the results matter as a reference point for how TIGIT pathway disruption can be combined with checkpoint therapy in solid tumors—an area where early clinical outcomes will heavily influence investment and partnering decisions.
-
RNA drugs regulation and safety evidence base
A new cross-platform review assessed adverse-event patterns across 18 FDA-approved RNA therapeutics. The analysis found that side-effect profiles depend more on delivery chemistry and administration route than on the RNA modality itself, with most events described as mild in the available reports. The paper also flagged a persistent evidence gap: long-term safety data remain thin relative to the depth of short-term tolerability information. For clinicians and developers, the finding reinforces that risk management for RNA drugs will continue to hinge on the specifics of delivery systems and routes. The review provides a consolidated reference point for ongoing pharmacovigilance discussions while underscoring why extended follow-up and registry-style data collection will remain important for next-generation RNA platforms.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.